Targeting cancer and neuropathy with histone deacetylase inhibitors: Two birds with one stone?

Current Cancer Drug Targets

Volumn 8, Issue 4, 2008, Pages 266-274

  Rodriguez Menendez, V ^a   Tremolizzo, L ^a   Cavaletti, G ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Cancer; Cisplatin; Histones; Neuropathy; Neuroprotection; Valproate

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CISPLATIN; HISTONE DEACETYLASE INHIBITOR; LEVACECARNINE; PACLITAXEL; PLATINUM DERIVATIVE; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD CLOTTING DISORDER; BRAIN DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DIABETIC NEUROPATHY; DIZZINESS; DROWSINESS; DRUG MECHANISM; DRUG TARGETING; DYSPEPSIA; DYSPHORIA; EPIGENETICS; FATIGUE; GENE SILENCING; HAIR LOSS; HEADACHE; HUMAN; LEUKEMIA; LIVER FUNCTION; LOW DRUG DOSE; LUNG CANCER; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEURAL TUBE DEFECT; NEUROPATHIC PAIN; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OVARY CANCER; PERIPHERAL NEUROPATHY; REVIEW; SEDATION; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; TERATOGENICITY; TESTIS CANCER; THROMBOCYTOPENIA; TREMOR; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; VALPROIC ACID;

EID: 45849101673     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908784533508     Document Type: Review

References (133)

1. Rice, J. C.; Allis, C. D. Code of silence. Nature 2001, 414, 258-261.
2. Jenuwein, T.; Allis, C. D. Translating the histone code. Science 2001, 293, 1074-1080.
3. Iizuka, M.; Smith, M. M. Functional consequences of histone modifications. Curr. Opin. Genet. Dev. 2003, 13, 154-160.
4. Szyf, M.; Detich, N. Regulation of the DNA methylation machinery and its role in cellular transformation. Prog. Nucleic Acid Res. Mol. Biol. 2001, 69, 47-79.
5. Becker, P. B.; Hörz, W. ATP-dependent nucleosome remodeling. Ann. Rev. Biochem. 2002, 71, 247-273.
6. Waterborg, J. H. Dynamics of histone acetylation in vivo. A function for acetylation turnover? Biochem. Cell Biol. 2002, 80, 363-378.
7. Allfrey, V. G.; Faulkner, R. M.; Minsky, A. E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. USA 1966, 51, 786-794.
8. Vogelauer, M.; Wu, J.; Suka, N.; Grunstein, M. Global histone acetylation and deacetylation in yeast. Nature 2000, 408, 495-498.
9. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1, 287-299.
10. Kuo, M. H.; vom Baur, E.; Struhl, K.; Allis, C. D. Gcn4 activator targets Gcn5 histone acetyltransferase to specific promoters independently of transcription. Mol. Cell. 2000, 6, 1309-1320.
11. Khochbin, S.; Kao, H. Y. Histone deacetylase complexes: functional entities or molecular reservoirs. FEBS Lett. 2001, 494, 141-144.
12. Roth, S. Y.; Denu, J. M.; Allis, C. D. Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70, 81-120.
13. Khochbin, S.; Verdel, A.; Lemercier, C.; Seigneurin-Berny, D. Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev. 2001, 11, 162-166.
14. de Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, A. B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370, 737-749.
15. Kornberg, R. D.; Lorch, Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999, 98, 285-294.
16. Vogelauer, M.; Wu, J.; Suka, N.; Grunstein, M. Global histone acetylation and deacetylation in yeast. Nature 2000, 408, 495-498.
17. Thiagalingam, S.; Cheng, K. H.; Lee, H. J.; Mineva, N.; Thiagalingam, A.; Ponte, J. F. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. N. Y. Acad. Sci. 2003, 983, 84-100.
18. Kim, T. Y.; Bang, Y. J.; Robertson, K. D. Histone deacetylase inhibitors for cancer therapy. Epigenetics 2006, 1, 14-23.
19. Krämer, O. H.; Göttlicher, M.; Heinzel, T. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 2001, 12, 294-300.
20. Elaut, G.; Rogiers, V.; Vanhaecke, T. The pharmaceutical potential of histone deacetylase inhibitors. Curr. Pharm. Des. 2007, 13, 2584-2620.
21. Villar-Garea, A.; Esteller, M. DNA demethylating agents and chromatin-remodelling drugs: which, how and why? Curr. Drug Metab. 2003, 4, 11-31.
22. Moradei, O.; Maroun, C. R.; Paquin, I.; Vaisburg, A. Histone deacetylase inhibitors: latest developments, trends and prospects. Curr. Med. Chem. Anticancer Agents 2005, 5, 529-560.
23. Santini, V.; Gozzini, A.; Ferrari, G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr. Drug Metab. 2007, 8, 383-393.
24. Davie, J. R. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 2003, 133, 2485S-2493S.
25. Richon, V. M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R. A.; Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA 1996, 93, 5705-5708.
26. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
27. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T.; Suzuki, T.; Tsuruo, T.; Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 1999, 96, 4592-4597.
28. Tremolizzo, L.; Rodriguez-Menendez, V.; DiFrancesco, J. C.; Sala, G.; Galbussera, A.; Appollonio, I.; Ferrarese, C. Huntington's disease and HDACi: would sulpiride and valproate be of therapeutic value? Med. Hypotheses 2007, 69, 964-965.
29. Kwon, H. J.; Owa, T., Hassig, C. A.; Shimada, J.; Schreiber, S. L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl. Acad. Sci. USA 1998, 95, 3356-3361.
30. Han, J. W.; Ahn, S. H.; Park, S. H.; Wang, S. Y.; Bae, G. U.; Seo, D. W.; Kwon, H. K.; Hong, S.; Lee, H. Y.; Leev, Y. W.; Lee, H. W. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 2000, 60, 6068-6074.
31. Perucca, E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002, 16, 695-714.
32. Phiel, C. J.; Zhang, F.; Huang, E. Y.; Guenther, M. G.; Lazar, M. A.; Klein, P. S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 2001, 276, 36734-36741.
33. Tremolizzo, L.; Carboni, G.; Ruzicka, W. B.; Mitchell, C. P.; Sugaya, I.; Tueting, P.; Sharma, R.; Grayson, D. R.; Costa, E.; Guidotti, A. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc. Natl. Acad. Sci. USA 2002, 99, 17095-17100.
34. Göttlicher, M.; Minucci, S.; Zhu, P.; Kramer, O. H.; Schimpf, A.; Giavara, S.; Sleeman, J. P.; Lo Coco, F.; Nervi, C.; Pelicci, P. G.; Heinzel, T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20, 6969-6978.
35. Tremolizzo, L.; Doueiri, M. S.; Dong, E.; Grayson, D. R.; Davis, J.; Pinna, G.; Tueting, P.; Rodriguez-Menendez, V.; Costa, E.; Guidotti, A. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol. Psychiatry 2005, 57, 500-509.
36. Göttlicher, M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann. Hematol. 2004, 83, 91-92.
37. Kim, M. S.; Kwon, H. J.; Lee, Y. M.; Baek, J. H.; Jang, J. E.; Lee, S. W.; Moon, E. J.; Kim, H. S.; Lee, S. K.; Chung, H. Y.; Kim, C. W.; Kim, K. W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 2001, 7, 437-443.
38. Nair, A. R.; Boersma, L. J.; Schiltz, L.; Chaudhry, M. A.; Muschel, R. J. Paradoxical effects of trichostatin A: inhibition of NF-Yassociated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. Cancer Lett. 2001, 166, 55-64.
39. Krämer, O. H.; Zhu, P.; Ostendorff, H. P.; Golebiewski, M.; Tiefenbach, J.; Peters, M. A.; Brill, B.; Groner, B.; Bach, I.; Heinzel, T.; Göttlicher, M. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003, 22, 3411-3420.
40. Detich, N.; Bovenzi, V.; Szyf, M. Valproate induces replication- independent active DNA demethylation. J. Biol. Chem. 2003, 278, 27586-27592.
41. Burton, B. S. On the propyl derivatives and decomposition products of ethylacetoacetate. Am. Chem. J. 1882, 3, 385-395.
42. Meunier, H.; Carraz, G.; Neunier, Y.; Eymard, P.; Aimard, M. [Pharmacodynamic properties of N-dipropylacetic acid]. Therapie 1963, 18, 435-438. French.
43. Loscher, W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 1999, 58, 31-59.
44. Michaelis, M.; Doerr, H. W.; Cinatl, J. Jr. Valproic acid as anticancer drug. Curr. Pharm. Des. 2007, 13, 3378-3393.
45. Bowden, C. L.; Singh, V. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr. Scand. 2005, 111, 13-20.
46. Kostrouchová, M.; Kostrouch, Z.; Kostrouchová, M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol. (Praha) 2007, 53, 37-49.
47. Blum, W.; Klisovic, R. B.; Hackanson, B.; Liu, Z.; Liu, S.; Devine, H.; Vukosavljevic, T.; Huynh, L.; Lozanski, G.; Kefauver, C.; Plass, C.; Devine, S. M.; Heerema, N. A.; Murgo, A.; Chan, K. K.; Grever, M. R.; Byrd, J. C.; Marcucci, G. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol. 2007, 25, 3884-3891.
48. Soriano, A. O.; Yang, H.; Faderl, S.; Estrov, Z.; Giles, F.; Ravandi, F.; Cortes, J.; Wierda, W. G.; Ouzounian, S.; Quezada, A.; Pierce, S.; Estey, E. H.; Issa, J. P.; Kantarjian, H. M.; Garcia-Manero, G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110, 2302-2308.
49. Kuendgen, A.; Gattermann, N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007, 110, 943-954.
50. Camphausen, K.; Tofilon, P. J. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol. 2007, 25, 4051-4056.
51. Karagiannis, T. C.; Kn, H.; El-Osta, A. The epigenetic modifier, valproic acid, enhances radiation sensitivity. Epigenetics 2006, 1, 131-137.
52. Segura-Pacheco, B.; Avalos, B.; Rangel, E.; Velazquez, D.; Cabrera, G. HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo. Genet. Vaccines Ther. 2007, 5, 10.
53. Catalano, M. G.; Poli, R.; Pugliese, M.; Fortunati, N.; Boccuzzi, G. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr. Relat. Cancer 2007, 14, 839-845.
54. Kuendgen, A.; Strupp, C.; Aivado, M.; Bernhardt, A.; Hildebrandt, B.; Haas, R.; Germing, U.; Gattermann, N. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004, 104, 1266-1269.
55. Kuendgen, A.; Knipp, S.; Fox, F.; Strupp, C.; Hildebrandt, B.; Steidl, C.; Germing, U.; Haas, R.; Gattermann, N. Results of a phase 2 study of valproic acid alone or in combination with alltrans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann. Hematol. 2005, 84, 61-66.
56. Kuendgen, A.; Schmid, M.; Schlenk, R.; Knipp, S.; Hildebrandt, B.; Steidl, C.; Germing, U.; Haas, R.; Dohner, H.; Gattermann, N. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106, 112-119.
57. Raffoux, E.; Chaibi, P.; Dombret, H.; Degos, L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005, 90, 986-988.
58. Pilatrino, C.; Cilloni, D.; Messa, E.; Morotti, A.; Giugliano, E.; Pautasso, M.; Familiari, U.; Cappia, S.; Pelicci, P. G.; Lo Coco, F.; Saglio, G.; Guerrasio, A. Increase in platelet count in older, poorrisk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005, 104, 101-109.
59. Cimino, G.; Lo-Coco, F.; Fenu, S. Sequential valproic acid/alltrans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res. 2006, 66, 8903-8911.
60. Garcia-Manero, G.; Kantarjian, H. M.; Sanchez-Gonzalez, B.; Yang, H.; Rosner, G.; Verstovsek, S.; Rytting, M.; Wierda, W.G.; Ravandi, F.; Koller, C.; Xiao, L.; Faderl, S.; Estrov, Z.; Cortes, J.; O'brien, S.; Estey, E.; Bueso-Ramos, C.; Fiorentino, J.; Jabbour, E.; Issa, J. P. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108, 3271-3279.
61. Bug, G.; Schwarz, K.; Schoch, C.; Kampfmann, M.; Henschler, R.; Hoelzer, D.; Ottmann, O. G.; Ruthardt, M. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 2007, 92, 542-545.
62. Candelaria, M.; Gallardo-Rincón, D.; Arce, C.; Cetina, L.; Aguilar-Ponce, J. L.; Arrieta, O.; González-Fierro, A.; Chávez-Blanco, A.; de la Cruz-Hernández, E.; Camargo, M. F.; Trejo-Becerril, C.; Pérez-Cárdenas, E.; Pérez-Plasencia, C.; Taja-Chayeb, L.; Wegman-Ostrosky, T.; Revilla-Vazquez, A.; Dueñas-González, A. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann. Oncol. 2007, 18, 1529-1538.
63. Blaheta, R. A.; Michaelis, M.; Natsheh, I.; Hasenberg, C.; Weich, E.; Relja, B.; Jonas, D.; Doerr, H. W.; Cinatl, J. Jr. Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumor cells to endothelium. Br. J. Cancer 2007, 96, 1699-1706.
64. Münster, P.; Marchion, D.; Bicaku, E.; Schmitt, M.; Lee, J. H.; DeConti, R.; Simon, G.; Fishman, M.; Minton, S.; Garrett, C.; Chiappori, A.; Lush, R.; Sullivan, D.; Daud, A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol. 2007, 25, 1979-1985.
65. Atmaca, A.; Al-Batran, S. E.; Maurer, A.; Neumann A.; Heinzel, T.; Hentsch, B.; Schwarz, S. E.; Hövelmann S.; Göttlicher, M.; Knuth, A.; Jäger, E. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br. J. Cancer 2007, 97, 177-182.
66. Fedier, A.; Dedes, K. J.; Imesch, P.; Von Bueren, A. O.; Fink, D. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int. J. Oncol. 2007, 31, 633-641.
67. Sghirlanzoni, A.; Pareyson, D.; Lauria, G. Sensory neuron diseases. Lancet Neurol. 2005, 4, 349-361.
68. Quasthoff, S.; Hartung, H. P. Chemotherapy-induced peripheral neuropathy. J. Neurol. 2002, 249, 9-17.
69. Windebank, A. J. Chemotherapeutic neuropathy. Curr. Opin. Neurol. 1999, 12, 565-571.
70. Ocean, A. J.; Vahdat, L. T. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 2004, 12, 619-625.
71. Peltier, A. C.; Russell, J. W. Recent advances in drug-induced neuropathies. Curr. Opin. Neurol. 2002, 15, 633-638.
72. Rosenberg, B.; Vancamp, L.; Krigas, T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature 1965, 205, 698-699.
73. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7, 573-584.
74. Cavaletti, G.; Marmiroli, P. Chemotherapy-induced peripheral neurotoxicity. Expert. Opin. Drug Saf. 2004, 3, 535-546.
75. McDonald, E. S.; Randon, K. R.; Knight, A.; Windebank, A. J. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol. Dis. 2005, 18, 305-313.
76. Barajon, I.; Bersani, M.; Quartu, M.; Del Fiacco, M.; Cavaletti, G.; Holst, J. J.; Tredici, G. Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Exp. Neurol. 1996, 138, 93-104.
77. Mollman, J. E. Cisplatin neurotoxicity. N. Engl. J. Med. 1990, 322, 126-127.
78. Baik, M. H.; Friesner, R. A.; Lippard, S. J. Theoretical study of cisplatin binding to purine bases: why does cisplatin prefer guanine over adenine? J. Am. Chem. Soc. 2003, 125, 14082-14092.
79. Huang, H.; Zhu, L.; Reid, B. R.; Drobny, G. P.; Hopkins, P. B. Solution structure of a cisplatin-induced DNA interstrand crosslink. Science 1995, 270, 1842-1845.
80. Meijer, C.; de Vries, E. G.; Marmiroli, P.; Tredici, G.; Frattola, L.; Cavaletti, G. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 1999, 20, 883-887.
81. Dzagnidze, A.; Katsarava, Z.; Makhalova, J.; Liedert, B.; Yoon, M. S.; Kaube, H.; Limmroth, V.; Thomale, J. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J. Neurosci. 2007, 27, 9451-9457.
82. Chaney, S. G.; Campbell, S. L.; Temple, B.; Bassett, E.; Wu, Y.; Faldu, M. Protein interactions with platinum-DNA adducts: from structure to function. J. Inorg. Biochem. 2004, 98, 1551-1559.
83. Eastman, A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990, 2, 275-280.
84. Scott, R. H.; Woods, A. J.; Lacey, M. J.; Fernando, D.; Crawford, J. H.; Andrews, P. L. An electrophysiological investigation of the effects of cisplatin and the protective actions of dexamethasone on cultured dorsal root ganglion neurons from neonatal rats. Naunyn Schmiedebergs Arch. Pharmacol. 1995, 352, 247-255.
85. Cece, R.; Petruccioli, M. G.; Cavaletti, G.; Barajon, I.; Tredici, G. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol. Histopathol. 1995, 10, 837-845.
86. Cavaletti, G.; Tredici, G.; Marmiroli, P.; Petruccioli, M. G.; Barajon, I.; Fabbrica, D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol. (Berl). 1992, 84, 364-371.
87. Malgrange, B.; Delree, P.; Rigo, J. M.; Baron, H.; Moonen G.Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. J. Neurosci. Methods 1994, 53, 111-122.
88. Hayakawa, K.; Sobue, G.; Itoh, T.; Mitsuma, T. Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro. Life Sci. 1994, 55, 519-525.
89. Lauria, G.; Lombardi, R.; Borgna, M.; Penza, P.; Bianchi, R.; Savino, C.; Canta, A.; Nicolini, G.; Marmiroli, P.; Cavaletti, G. Intraepidermal nerve fibre density in rat foodpad: neuropathologicneurophysiologic correlation. J. Peripher. Nerv. Syst. 2005, 10, 199-205.
90. Schmidt, Y.; Unger, J. W.; Bartke, I.; Reiter, R. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Exp. Neurol. 1995, 132, 16-23.
91. ter Laak, M. P.; Hamers, F. P.; Kirk, C. J.; Gispen, W. H. rhGGF2 protects against cisplatin-induced neuropathy in the rat. J. Neurosci. Res. 2000, 60, 237-244.
92. Holmes, J.; Stanko, J.; Varchenko, M.; Ding, H.; Madden, V. J.; Bagnell, C. R.; Wyrick, S. D.; Chaney, S. G. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol. Sci. 1998, 46, 342-351.
93. Fischer, S. J.; McDonald, E. S.; Gross, L.; Windebank, A. J. Alterations in cell cycle regulation underlie cisplatin induced apoptosis of dorsal root ganglion neurons in vivo. Neurobiol. Dis. 2001, 8, 1027-1035.
94. Kochar, D. K.; Rawat, N.; Agrawal, R. P.; Vyas, A.; Beniwal, R.; Kochar, S. K.; Garg, P. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 2004, 97, 33-38.
95. Tremont-Lukats, I. W.; Megeff, C.; Backonja, M. M. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 2000, 60, 1029-1052.
96. Cui, S. S.; Yang, C. P.; Bowen, R. C.; Bai, O.; Li, X. M.; Jiang, W.; Zhang, X. Valproic acid enhances axonal regeneration and recovery of motor function after sciatic nerve axotomy in adult rats. Brain Res. 2003, 975, 229-236.
97. Rodriguez-Menendez, V.; Gilardini, A.; Bossi, M.; Canta, A.; Oggioni, N.; Carozzi, V.; Tremolizzo, L.; Cavaletti, G. Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study. Anticancer Res. 2008, 28, 335-342.
98. Fritz, I. B. Carnitine and its role in fatty acid metabolism. Adv. Lipid Res. 1963, 1, 285-334.
99. Bremer, J. The role of carnitine in intracellular metabolism. J. Clin. Chem. Clin. Biochem. 1990, 28, 297-301.
100. Furlong, J. H. Acetyl-L-carnitine: metabolism and applications in clinical practice. Alter. Med. Rev. 1996, 1, 85-93.
101. Montgomery, S. A.; Thal, L. J.; Amrein, R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int. Clin. Psychopharmacol. 2003, 18, 61-71.
102. Abdul, H. M.; Calabrese, V.; Calvani, M.; Butterfield, D. A. Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J. Neurosci. Res. 2006, 84, 398-408.
103. Bianchetti, A.; Rozzini, R.; Trabucchi, M. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr. Med. Res. Opin. 2003, 19, 350-353.
104. Pettegrew, J. W.; Levine, J.; Gershon, S.; Stanley, J. A.; Servan-Schreiber, D.; Panchalingam, K.; McClure, R. J. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord. 2002, 4, 61-66.
105. Xie, J.; Zeng, Q.; Wang, L. The protective effect of L-carnitine on ischemia-reperfusion heart. J. Huazhong Univ. Sci. Tech. Med. Sci. 2006, 26, 188-191.
106. Tempesta, E.; Troncon, R.; Janiri, L.; Colusso, L.; Riscica, P.; Saraceni, G.; Gesmundo, E.; Calvani, M.; Benedetti, N.; Pola, P. Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism. Int. J. Clin. Pharmacol. Res. 1990, 10, 101-107.
107. De Grandis, D.; Minardi, C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term randomized, double-blind, placebo-controlled study. Drugs R.D. 2002, 3, 223-231.
108. Sima, A. A. Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data. CNS Drugs 2007, 21, 13-23.
109. Youle, M.; Osio, M.; ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med. 2007, 8, 241-250.
110. Herzmann, C.; Johnson, M. A.; Youle, M. Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clin. Trials 2005, 6, 344-350.
111. Osio, M.; Muscia, F.; Zampini, L.; Nascimbene, C.; Mailland, E.; Cargnel, A.; Mariani, C. Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J. Peripher. Nerv. Syst. 2006, 11, 72-76.
112. Sima, A. A.; Calvani, M.; Mehra, M.; Amato, A.; Acetyl-L-Carnitine Study Group. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic dia betic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005, 28, 89-94.
113. Ghirardi, O.; Lo Giudice, P.; Pisano, C.; Vertechy, M.; Bellucci, A.; Vesci, L.; Cundari, S.; Miloso, M.; Rigamonti, L. M.; Nicolini, G.; Zanna, C.; Carminati, P. Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res. 2005, 25, 2681-2687.
114. Pisano, C.; Pratesi, G.; Laccabue, D.; Zunino, F.; Lo Giudice, P.; Bellucci, A.; Pacifici, L.; Camerini, B.; Vesci, L.; Castorina, M.; Cicuzza, S.; Tredici, G.; Marmiroli, P.; Nicolini, G.; Galbiati, S.; Calvani, M.; Carminati, P.; Cavaletti, G. Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin. Cancer Res. 2003, 9, 5756-5767.
115. Flatters, S. J.; Xiao, W. H.; Bennett, G. J. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci. Lett. 2006, 397, 219-223.
116. De Grandis, D. Acetyl-L-carnitine treatment of chemotherapy/induced peripheral neuropathy: a short review. CNS Drugs 2007, 21, 39-43.
117. Chiechio, S.; Copani, A.; Gereau, R. W. 4th; Nicoletti, F. Acetyl-L-carnitine in neuropathic pain: experimental data. CNS Drugs 2007, 21, 31-38.
118. Head, K. A. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern. Med. Rev. 2006, 11, 294-329.
119. Maestri, A.; De Pasquale Ceratti, A.; Cundari, S.; Zanna, C.; Cortesi, E.; Crino, L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005, 91, 135-138.
120. Tabolacci, E.; Pietrobono, R.; Moscato, U.; Oostra, B. A.; Chiurazzi, P.; Neri, G. Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur. J. Hum. Genet. 2005, 13, 641-648.
121. Chauhan, N. B.; Siegel, G. J. Effect of PPF and ALCAR on the induction of NGF- and p75-mRNA and on APP processing in Tg257 brain. Neurochem. Int. 2003, 43, 225-233.
122. Taglialatela, G.; Navarra, D.; Cruciani, R.; Ramacci, M. T.; Alema, G. S.; Angelucci, L. Acetyl-L-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats. Exp. Gerontol. 1994, 29, 55-66.
123. Faraco, G.; Pancani, T.; Formentini, L.; Mascagni, P.; Fossati, G.; Leoni, F.; Moroni, F.; Chiarugi, A. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 2006, 70, 1876-1884.
124. Kim, H. J.; Rowe, M.; Ren, M.; Hong, J. S.; Chen, P. S.; Chuang, D. M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 2007, 321, 892-901.
125. Morland, C.; Boldingh, K. A.; Iversen, E. G.; Hassel, B. Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high-affinity glutamate uptake. J. Cereb. Blood Flow Metab. 2004, 24, 1226-1234.
126. Hockly, E.; Richon, V. M.; Woodman, B.; Smith, D. L.; Zhou, X.; Rosa, E.; Sathasivam, K.; Ghazi-Noori, S.; Mahal, A.; Lowden, P. A.; Steffan, J. S.; Marsh, J. L.; Thompson, L. M.; Lewis, C. M.; Marks, P. A.; Bates, G. P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 2003, 100, 2041-2046.
127. Sadri-Vakili, G.; Cha, J. H. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr. Alzheimer Res. 2006, 3, 403-408.
128. Minamiyama, M.; Katsuno, M.; Adachi, H.; Waza, M.; Sang, C.; Kobayashi, Y.; Tanaka, F.; Doyu, M.; Inukai, A.; Sobue, G. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2004, 13, 1183-1192.
129. Butler, R.; Bates, G. P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci. 2006, 7, 784-796.
130. Sugai, F.; Yamamoto, Y.; Miyaguchi, K.; Zhou, Z.; Sumi, H.; Hamasaki, T.; Goto, M.; Sakoda, S. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. 2004, 20, 3179-3183.
131. Ryu, H.; Smith, K.; Camelo, S. I.; Carreras, I.; Lee, J.; Iglesias, A. H.; Dangond, F.; Cormier, K. A.; Cudkowicz, M. E.; Brown, R. H. Jr.; Ferrante, R. J. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 2005, 93, 1087-1098.
132. Tremolizzo, L.; Rodriguez-Menendez, V.; Sala, G.; Di Francesco, J. C.; Ferrarese, C. Valproate and HDAC inhibition: a new epigenetic strategy to mitigate phenotypic severity in ALS? Amyotroph. Lateral Scler. Other. Motor Neuron. Disord. 2005, 6, 185-186.
133. Rouaux, C.; Panteleeva, I.; René, F.; Gonzalez de Aguilar, J. L.; Echaniz-Laguna, A.; Dupuis, L.; Menger, Y.; Boutillier, A. L.; Loeffler, J. P. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci. 2007, 27, 5535-5545.